Artikel
Virological medical quality management – 10 years follow-up
Virologisch Medizinisches Qualitätsmanagement – 10-Jahres-Follow-up
Suche in Medline nach
Autoren
Veröffentlicht: | 2. Juni 2010 |
---|
Gliederung
Text
Objectives: All antiretroviral treatments and their virological efficacy were analysed in a German Cohort over the past 10 years.
Methods: Between 997 (in 2000) and 2,452 (in 2009) data sets were collected from up to 23 medical-centres in NRW. ART were divided into combinations containing either 3 nucleos(t)ide analogues (NRTI), 2 NRTI + 1 protease-inhibitor (PI), 2 NRTI + 1 non-nucleoside-reverse-transcriptase-inhibitor (NNRTI) and all other combinations as “other” regimens. Therapy success was defined as HIV1-RNA < 40 copies/ml. Additionally, the proportion and efficacy of firstline regimens were evaluated.
Results: The moderately increasing number of patients receiving ART (from 77.1% in 2000 to 81.8% in 2009) was accompanied by a remarkable increase of therapy success from 71.9% to 85.5%, respectively. There were no greater changes in the prescribing patterns concerning the antiretroviral regimens. Preferred combinations in 2009 were 2 NRTI + 1 PI with 43.2% followed by NNRTI combinations (39.1%) and “other” regimens (13.1%) and combinations with 3 NRTIs (2.6%).
Until 2009 therapy success increased as follows: 2 NRTI + 1 PI: 68.7% to 83.4%; 2 NRTI + 1 NNRTI: 72.8% to 90.4% and other regimens: 44.5% to 77.2%. Last year 30.5% of the treated patients received a firstline regimen with a success rate of 84.0%, 1.5% lower than overall success. Firstline regimens parted in: 3 NRTI with 4.3%; 2 NRTI + 1 PI with 42.9%; 2 NRTI + 1 NNRTI with 48.7% and other regimens with 4.4%.
New approved drugs counted as “other” regimens had a proportion of: Integrase-Inhibitors 3.4%, and Fusion-Inhibitors 0.3% and CCR5 antagonists 1.1% and showed a therapy success of 84.1%, 42.9% and 69.6%, respectively.
Conclusions: Over the time all regimens achieved a higher therapy success which can be due to a simplified mode of intake, improved drug formulations, new substance classes or treatment strategies. Moreover, the feedback given to the individual centres can lead to an improvement of quality in HIV-treatment. Lower firstline success is partly caused by recently started therapies not reaching undetectable viral loads yet. Mainly Fusion Inhibitors are used in deep salvage which might be a reason for the lower success of this drug class. With rising prescriptions of the new approved drug classes they will be considered more in detail in future evaluations.